Nicole V. Bremer

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents”.

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

British Journal of Cancer(2024)10.1038/s41416-024-02760-1

N/A

0DataRank · unranked

13 citations

Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina +17 more

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors

Clinical and Translational Medicine(2025)10.1002/ctm2.70338

N/A

0DataRank · unranked

3 citations

Valentina Foglizzo, Jason Chang, Natasha Rekhtman, Ann Elizabeth Sisk, Jamie Gibson +20 more

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology(2025)10.1002/1878-0261.70155

N/A

0DataRank · unranked

0 citations

Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo +9 more